Avenue Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Notes Payable (Details Textual)

Notes Payable (Details Textual) - USD ($)		1 Months Ended				11 Months Ended	12 Months Ended
Notes Payable (Details Textual) - USD ($)	Jul. 05, 2017	Jul. 25, 2017	Jun. 26, 2017	Dec. 30, 2016	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2017	Dec. 31, 2016	Feb. 28, 2015
Repayments of Notes Payable						$ 0	$ 3,000,000	$ 0
Debt Instrument, Periodic Payment, Interest		$ 100,000
Stock Issued During Period, Shares, New Issues					250,000
Stock Issued During Period, Value, New Issues							948,000	5,000
Notes Payable						2,703,000	0	2,826,000
Convertible Notes Payable, Current							0	200,000
Convertible Debt, Fair Value Disclosures							200,000
Debt Conversion, Converted Instrument, Shares Issued			49,748
IPO [Member]
Stock Issued During Period, Value, New Issues			$ 6,325,000
Fortress Biotech, Inc [Member] \| IPO [Member]
Stock Issued During Period, Shares, New Issues			125,000
Stock Issued During Period, Value, New Issues			$ 800,000
NSC Notes Memebers [Member]
Repayments of Notes Payable	$ 3,000,000						3,000,000
Debt Instrument, Periodic Payment, Interest	$ 2,000
Interest Expense, Debt						200,000	300,000	400,000
Debt Instrument, Unamortized Discount						$ 297,000	$ 0	174,000
NSC Notes Memebers [Member] \| IPO [Member]
Stock Issued During Period, Value, New Issues			125,000
NSC Notes Memebers [Member] \| Fortress Biotech, Inc [Member]
Debt Instrument, Term							10 years
Debt Instrument, Interest Rate, Stated Percentage							8.00%
Debt Instrument, Maturity Date, Description							The note matures in 36 months, provided that during the first 24 months Fortress can extend the maturity date by six months. No principal amount will be due for the first 24 months (or the first thirty30 months, if the maturity date is extended).and monthly thereafter until maturity.
Contingently Issuable Warrants Percentage							25.00%
Notes Payable							$ 0
Debt Issuance Costs, Net								$ 200,000
Debt Instrument, Interest Rate, Effective Percentage								13.10%
Debt Instrument, Unamortized Discount								$ 100,000
NSC Notes Memebers [Member] \| Avenue Therepeutics parent co [Member]
Debt Instrument, Face Amount			$ 3,000,000						$ 10,000,000
Convertible Note Payable [Member] \| Fortress Biotech, Inc [Member]
Debt Instrument, Term				18 months
Convertible Notes Payable, Current								$ 200,000
Debt Instrument Interest Rate Stated Percentage current Year				5.00%
Debt Instrument Interest Rate Stated Percentage after Twelve Month				8.00%
Proceeds from Issuance or Sale of Equity				$ 10,000,000
Net Proceeds From Issuance Of Private Placement After Paying Fees				100,000
Payments For Placement Fee				30,000
Payments for Other Fees				4,000
Professional Fees				14,000
Class Of Warrant Or Right Value Of Securities Called By Warrants Or Rights				$ 10,000
Class Of Warrant Or Right Expiration Period				10 years
Convertible Note Payable [Member] \| Fortress Biotech, Inc [Member] \| Conversion One [Member]
Debt Instrument, Convertible, Terms of Conversion Feature				(a) the lowest price per share at which equity securities of Avenue are sold in such sale less a 33% discount and (b) a per share price based on a pre-offering valuation of $30.0 million divided by the number of common shares outstanding on a fully-diluted basis
Convertible Note Payable [Member] \| Fortress Biotech, Inc [Member] \| Conversion Two [Member]
Debt Instrument, Convertible, Terms of Conversion Feature				(a) a discount to the price per share being paid in the Sale of Avenue equal to 33% or (b) the quotient resulting from dividing (x) $30.0 million by (y) the fully-diluted common stock of Avenue outstanding immediately prior to the Sale of Avenue (excluding the notes)